Isoniazid or Rifampicin and Isoniazid Preventive Therapy for children exposed to TB - the IRIPT trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201101000273931

Enrollment

880

Registered

2011-01-14

Start date

2011-01-18

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis Paediatrics

Interventions

Isoniazid

Rifampicin and Isoniazid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Household contact of TB case 2)Age5mm) 3)Informed consent given by parent or person in loco parentis

Exclusion criteria

Exclusion criteria: 1)Active TB at time of inclusion 2)HIV-positive child receiving HAART 3)Known liver disease or allergy to INH or RIF 4)Pregnancy (all girls>12 years will get a pregnancy test) 5)A history of seizures

Design outcomes

Primary

Measure	Time frame
Adherence to therapy (80% of pills taken will be considered good adherence)	—

Secondary

Measure	Time frame
Mortality;TB incidence;TST conversion;Adverse events	—

Countries

Guinea-Bisseu

Contacts

Public ContactGrethe Lemvik

PhD student, Bandim Health Project/Statens Serum Institut

grethe.lemvik@ki.au.dk+245 6751431

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026